Daiichi Sankyo

482 articles about Daiichi Sankyo

• 

  Daiichi Sankyo, Syneos Health Eye New Cancer Therapies with Collaboration Agreement

  6/1/2020

  Daiichi Sankyo announced on May 28 that it had entered an agreement with Syneos Health to form a coalition dedicated to bringing new cancer therapies to patients in a safe and effective manner.

• ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial

  5/29/2020

  Results from the ongoing phase 2 DESTINY-Lung01 trial showed Daiichi Sankyo Company, Limited and AstraZeneca’s ENHERTU® achieved a clinically meaningful tumor response in patients with HER2 mutant unresectable and/or metastatic non-squamous non-small cell lung cancer whose disease had progressed following one or more systemic therapies.

• ENHERTU (fam-trastuzumab deruxtecan-nxki) Achieved a Tumor Response Rate of 45.3% in Patients With HER2-Positive Metastatic Colorectal Cancer in Phase II DESTINY-CRC01

  5/29/2020

  Results from the ongoing Phase II DESTINY-CRC01 trial showed AstraZeneca and Daiichi Sankyo Company, Limited’s ENHERTU® demonstrated clinically meaningful activity in patients with HER2-positive unresectable and/or metastatic colorectal cancer who received at least two prior lines of standard treatment.

• Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Non-Small Cell Lung Cancer

  5/29/2020

  Daiichi Sankyo Company, Limited announced that it has entered into a clinical trial collaboration agreement with a subsidiary of Merck & Co., Inc., Kenilworth, New Jersey, U.S.A., known as MSD outside the United States and Canada, to evaluate the combination of DS-1062, a TROP2 directed DXd antibody drug conjugate, and KEYTRUDA® in patients with previously-treated advanced or metastatic non-small cell lung cancer without actionable genomic alterations.

• Daiichi Sankyo and Syneos Health® Form Strategic Coalition for Development of Daiichi Sankyo’s ADC Oncology Pipeline

  5/28/2020

  Daiichi Sankyo and Syneos Health ® Form Strategic Coalition for Development of Daiichi Sankyo’s ADC Oncology Pipeline  Coalition ignites strategic insights sooner to accelerate patient access

• Daiichi Sankyo Launches ENHERTU® in Japan for Patients with HER2 Positive Unresectable or Metastatic Breast Cancer

  5/26/2020

  ENHERTU is the second innovative oncology medicine to be launched in Japan from the oncology pipeline of Daiichi Sankyo in the past year

• ENHERTU® Granted Orphan Drug Designation in the U.S. for Gastric Cancer

  5/22/2020

  Daiichi Sankyo Company, Limited and AstraZeneca’s ENHERTU® has been granted Orphan Drug Designation in the U.S. for the treatment of patients with gastric cancer, including gastroesophageal junction cancer.

• Daiichi Sankyo Initiates Clinical Trial with 5th DXd ADC, DS-6157, in Collaboration with Sarah Cannon Research Institute

  5/22/2020

  Daiichi Sankyo Initiates Clinical Trial with 5 th DXd ADC, DS-6157, in Collaboration with Sarah Cannon Research Institute First-in-human phase 1 trial initiated with DS-6157, a GPR20 directed ADC, in patients with advanced gastrointestinal stromal tumor (GIST) GIST is a rare cancer of the digestive tract with limited treatment options available to patients who progress on standard TKI therapy DS-6157 is the fifth DXd ADC from the oncology pip

• ENHERTU® Granted Breakthrough Therapy Designation in the U.S. for HER2 Mutant Metastatic Non-Small Cell Lung Cancer

  5/18/2020

  Daiichi Sankyo Company, Limited and AstraZeneca’s ENHERTU® has been granted Breakthrough Therapy Designation in the U.S.

• ENHERTU Granted Breakthrough Therapy Designation in the US for HER2-Mutant Metastatic Non-Small Cell Lung Cancer

  5/18/2020

  AstraZeneca and Daiichi Sankyo Company, Limited’s ENHERTU® has been granted Breakthrough Therapy Designation in the US for the treatment of patients with metastatic non-small cell lung cancer whose tumors have a HER2 mutation and with disease progression on or after platinum-based therapy.

• Daiichi Sankyo to Present New Research Data Across DXd ADC Portfolio at 2020 ASCO Annual Meeting

  5/13/2020

  Daiichi Sankyo Company, Limited announced that it will present new research data across its DXd antibody drug conjugate portfolio at the 2020 American Society of Clinical Oncology Virtual Scientific Program to be held May 29 to May 31.

• Daiichi Sankyo Submits Supplemental New Drug Application for Trastuzumab Deruxtecan in Japan for Treatment of Patients with HER2 Positive Metastatic Gastric Cancer

  5/7/2020

  Trastuzumab deruxtecan to receive expedited review by Japan MHLW based on SAKIGAKE designation for second potential indication in Japan

• Ultragenyx Enters into Strategic Partnership with Daiichi Sankyo for Gene Therapy Manufacturing Technology

  4/1/2020

  Daiichi Sankyo granted non-exclusive license to Ultragenyx HeLa manufacturing platform

• Daiichi Sankyo Submits Application for CAR T Therapy Axicabtagene Ciloleucel for Treatment of Patients with Certain Relapsed/Refractory B-cell Lymphomas in Japan

  3/30/2020

  NDA submission based on previous pivotal trial data and a phase 2 study in Japan in patients with certain relapsed/refractory B-cell lymphomas

• ENHERTU® Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic Breast Cancer

  3/25/2020

  ENHERTU ® Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic Breast Cancer Approval based on the pivotal DESTINY-Breast01 trial represents third approval ever under the conditional early approval system in Japan, and follows recent U.S. accelerated approval of ENHERTU ® ENHERTU ® represents the second innovative treatment from the oncology pipeline of Daiichi Sankyo to be approved for use in Japan in past

• ERS Genomics Licenses CRISPR Gene Editing Technology to Daiichi Sankyo to Support Internal Research and Development

  1/13/2020

  ERS Genomics Limited, which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, announced the signing of a license agreement with Daiichi Sankyo, a global pharmaceutical company with corporate origins in Japan.

• ENHERTU® Approved in the U.S. for HER2 Positive Unresectable or Metastatic Breast Cancer Following Two or More Prior Anti-HER2-Based Regimens

  12/20/2019

  Accelerated Approval of Daiichi Sankyo and AstraZeneca’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) based on the pivotal DESTINY-Breast01 trial that showed clinically meaningful and durable responses

• 

  Seattle Genetics Claims Arbitration Rights in Daiichi Sankyo ADC Dispute

  12/3/2019

  In a filing with the court, Seattle Genetics claimed the right to arbitration to resolve the dispute with Daiichi Sankyo, as is required by the 2008 collaboration agreement.

• Global Diabetic Neuropathy Drugs Market 2019-2023 - Evolving Opportunities with DAIICHI SANKYO COMPANY LIMITED and Eli Lilly and Company | Technavio

  11/14/2019

  Technavio has announced its latest market research report titled global diabetic neuropathy drugs market 2019-2023

• Seattle Genetics Submits Arbitration Demand Against Daiichi Sankyo Over Technology Ownership

  11/12/2019

  Seattle Genetics has been abiding by the agreement’s dispute resolution provisions.